---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004174"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:48:50.768651+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics FY2023 rev $19.6M (+80% YoY); GAAP net loss $14.5M; Nasdaq delisted; debt paid

## Summary
- Full year 2023 net revenue $19.6M, up 80% YoY; Twirla demand up 131% to 243,841 cycles.
- GAAP net loss $14.5M ($6.71/share); non-GAAP net loss $21.2M ($9.84/share); OPEX down 33% to $30.5M.
- Cash $2.5M at Dec 31, 2023; raised $4.8M via warrant exercise in Feb 2024; paid off Perceptive Advisors debt in Q1 2024.
- Delisted from Nasdaq on Mar 25; now trading on OTC under AGRX; does not expect impact on business.
- Twirla demand rebounding in Q1 2024; January retail cycles (26,464) highest single month since launch.

## SEC filing metadata
- accession: 0001558370-24-004174
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/0001558370-24-004174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/agrx-20240328x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004174
- JSON: https://secwatch.observer/filing/0001558370-24-004174.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004174.txt

## Key facts
- Earnings Releases
  AGILE THERAPEUTICS INC reported the three months and fiscal year ended December 31, 2023 results: revenue Net revenue for the fourth quarter 2023 was $3.6 million.
  - Period: the three months and fiscal year ended December 31, 2023
  - Revenue: Net revenue for the fourth quarter 2023 was $3.6 million
  - Result: reported results
  source text: On March 28, 2024, Agile Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and an update on the Company’s operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/0001558370-24-004174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.